Drug Discovery & Development | EC approves Roche's SC formulation of MabThera for common forms of non ... News-Medical.net Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large ... Europe OKs New Formula of Roche Cancer Drug Halozyme Platform Wins EC Approval for Roche's MabThera SC Halozyme: European Approval Of Roche's MabThera SC For Non-Hodgkin ... |
